Skip to main content
NewslettersWatchlist

Halozyme Therapeutic(HALO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low38.08
Day High38.81
Open:38.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
PR Newswire
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
PR Newswire
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
PR Newswire
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
OTOS Inc.
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar
PR Newswire
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR Newswire
Halozyme To Report Second Quarter 2023 Financial and Operating Results
PR Newswire
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
PR Newswire
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
PR Newswire
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
PR Newswire
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR Newswire
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
PR Newswire
Halozyme to Present at Upcoming Investor Conferences
PR Newswire
Halozyme To Report First Quarter 2023 Financial and Operating Results
Newswire.ca
Halo Collective Announces Management Cease Trade Order
PR Newswire
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
PR Newswire
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
PR Newswire
Halozyme Appoints Barbara Duncan to its Board of Directors
PR Newswire
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
PR Newswire
Halozyme Provides 2023 Financial Guidance and Outlook
Newswire.ca
Halo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
Newswire.ca
Halo Collective Reports Third Quarter 2022 Financial Results
Newswire.ca
Halo Collective Enters into Convertible Promissory Note for Aggregate Principal Amount of Up To C$5 Million
PR Newswire
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
Newswire.ca
Halo Announces Effective Date of Share Consolidation
PR Newswire
Halozyme to Report Third Quarter 2022 Financial and Operating Results
Newswire.ca
Halo Announces Update to Proposed Share Consolidation
Newswire.ca
Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon
Newswire.ca
Halo Announces Share Consolidation
Newswire.ca
Halo Collective and Alpha Blue Ocean Agree to Early Termination of Loan and Convertible Debentures Agreements
PR Newswire
Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
Newswire.ca
/R E P E A T -- Halo Collective Reports Second Quarter 2022 Financial Results/

Profile

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.